Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
denali therapeutics
Overview
Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, a field with significant unmet medical need. Operating within the biotechnology and pharmaceutical sectors, Denali specializes in developing novel therapeutics that can effectively cross the blood-brain barrier, a major challenge in treating brain disorders. Their market position is characterized by a focus on innovative science, strategic collaborations with leading pharmaceutical companies, and a robust pipeline of potential disease-modifying treatments for conditions such as Alzheimer's, Parkinson's, and ALS. They are known for their Transport Vehicle (TV) technology, which is designed to deliver therapeutics across the blood-brain barrier, giving them a competitive advantage in the neurodegenerative disease space.
denali therapeutics's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 15 |
Consulting | 3 |
Service | 1 |
Design | 0 |
Education | 2 |
Denali Therapeutics' department distribution strongly indicates a research and development-centric biotechnology company prioritizing scientific innovation and clinical advancement. The 'Research' department's significant size (149 employees) underscores the company's commitment to discovering and developing novel therapies. The substantial 'Medical' affairs team (35 employees) reflects the company's focus on clinical trials, regulatory submissions, and preparing for the potential commercialization of drug candidates, indicating a pipeline nearing late-stage development. The 'Operations' department (35 employees) signals growing needs for manufacturing, supply chain management, and quality control as they progress through clinical trials. The 'Technical' roles (23 employees) likely encompass process development, formulation, and potentially some aspects of drug manufacturing; however, given the size, Denali may still rely on collaborations and external partnerships for advanced manufacturing solutions, a common strategy in the biotech industry. The relatively smaller sizes of departments such as 'Finance,' 'HR,' 'Legal,' 'Marketing,' and 'Sales' suggest the company is still in a growth phase focusing primarily on R&D. The comparatively large 'Other Department' category (77 employees) most likely encompasses specialized R&D functions such as bioanalytical development, translational science, and specialized research support roles critical to their scientific pursuits. This workforce structure aligns with a business model that prioritizes scientific discovery and early-stage clinical development, with a likely plan to expand commercial capabilities as products approach market approval.
denali therapeutics's employees by locations
Employee Count by Country
Total: 401 employees
Denali Therapeutics exhibits a predominantly domestic workforce distribution with a significant concentration of employees in the United States (383 employees), reflecting its origin and core operational base. This suggests that their headquarters, key research facilities, and primary clinical development activities are located in the US, which is common for biotech companies engaged in advanced drug development and clinical trials. The presence of a notable team in Switzerland (14 employees) indicates a strategic decision to leverage European talent, access specific scientific expertise, or establish collaborations within the Swiss biotech hub. The limited presence in other countries, such as Spain, Italy, Turkey, and Kuwait (each with one employee), likely represents remote roles, individual consultants, or participation in international research collaborations. The distribution supports a primarily US-centric operational and R&D footprint with a smaller international presence focused on strategic European access. The regional employee distribution confirms the strong concentration in Northern America, particularly the United States. As Denali progresses its clinical pipeline and contemplates global market access, it may need to diversify its geographic distribution; however, its current footprint is suitable for its stage of development, allowing it to focus on the US market while strategically accessing European expertise. This strategy reflects a pragmatic approach to international expansion, prioritizing key regions for specific strategic purposes, rather than a widespread global distribution at this stage.
Want to stay ahead of denali therapeutics's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early